ML604086|cas:850330-18-6|西域试剂

ML604086,99.80%

产品编号：Bellancom-124416| CAS NO：850330-18-6| 分子式：C₂₇H₃₂N₄O₄S| 分子量：508.63

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124416	￥2000.00	杭州北京（现货）
Bellancom-124416	￥3500.00	杭州北京（现货）
Bellancom-124416	￥7400.00	杭州北京（现货）
Bellancom-124416	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ML604086

产品介绍

ML604086 是一种选择性的 CCR8 抑制剂，抑制循环T细胞上 CCL1 与 CCR8 结合。ML604086 抑制 CCL1 介导的趋化作用，增加细胞内 Ca²⁺浓度。

生物活性

ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca²⁺ concentrations.

体外研究

ML604086 (0-100 µM) inhibits CCL1 mediated chemotaxis and increases in intracellular Ca²⁺ concentrations of cell lines stably expressing cyno CCR8 with IC₅₀s of 1.3 µM and 1.0 µM, respectively.
ML604086 (10, 30 µM; 64 h) inhibits CCL1 binding to CCR8 on CD4 T-cells, and inhibits the serotonin receptor 5HT1a with the inhibition rate of 30%, 70% at 10, 30 µM respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ML604086 (1.038 mg/kg; intravenous infusion) shows no effect on airway eosinophilia, pro-inflammatory cytokine production or airway resistance and compliance in Macaca fascicularis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	3.0-5.0 kg male and female adult Macaca fascicularis (primate model of asthma)
Dosage:	1.038 mg/kg
Administration:	Intravenous infusion
Result:	Did not effected the Changes in airway resistance and compliance induced by allergen provocation and increasing concentrations of methacholine.

体内研究

ML604086 (1.038 mg/kg; intravenous infusion) shows no effect on airway eosinophilia, pro-inflammatory cytokine production or airway resistance and compliance in Macaca fascicularis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	3.0-5.0 kg male and female adult Macaca fascicularis (primate model of asthma)
Dosage:	1.038 mg/kg
Administration:	Intravenous infusion
Result:	Did not effected the Changes in airway resistance and compliance induced by allergen provocation and increasing concentrations of methacholine.

性状

Solid

溶解性数据

In Vitro:

DMSO : 120 mg/mL (235.93 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9661 mL	9.8303 mL	19.6607 mL
5 mM	0.3932 mL	1.9661 mL	3.9321 mL
10 mM	0.1966 mL	0.9830 mL	1.9661 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 6.25 mg/mL (12.29 mM); Clear solution

此方案可获得 ≥ 6.25 mg/mL (12.29 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 6.25 mg/mL (12.29 mM); Clear solution

此方案可获得 ≥ 6.25 mg/mL (12.29 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。